BMJ Open Delays between the onset of symptoms and first rheumatology consultation in patients with rheumatoid arthritis in the UK: an observational study

Rebecca Jayne Stack, Peter Nightingale, Clare Jinks, Karen Shaw, Sandy Herron-Marx, Rob Horne, Chris Deighton, Patrick Kiely, Christian Mallen, Karim Raza, On behalf of the DELAY study syndicate

ABSTRACT

Objective To investigate delays from symptom onset to rheumatology assessment for patients with a new onset of rheumatoid arthritis (RA) or unclassified arthritis.

Methods Newly presenting adults with either RA or unclassified arthritis were recruited from rheumatology clinics. Data on the length of time between symptom onset and first seeing a GP (patient delay), between first seeing a general practitioner (GP) and being referred to a rheumatologist (general practitioner delay) and being seen by a rheumatologist following referral (hospital delay) were captured.

Results 822 patients participated (563 female, mean age 55 years). The median time between symptom onset and seeing a rheumatologist was 27.2 weeks (IQR 14.1–66 weeks); only 20% of patients were seen within the first 3 months following symptom onset. The median patient delay was 5.4 weeks (IQR 1.4–26.3 weeks). Patients who purchased over-the-counter medications or used ice/heat packs took longer to seek help than those who did not. In addition, those with a palindromic or an insidious symptom onset delayed for longer than those with a non-palindromic or acute onset. The median general practitioner delay was 6.9 weeks (IQR 2.3–20.3 weeks). Patients made a mean of 4 GP visits before being referred. The median hospital delay was 4.7 weeks (IQR 2.9–7.5 weeks).

Conclusion This study identified delays at all levels in the pathway towards assessment by a rheumatologist. However, delays in primary care were particularly long. Patient delay was driven by the nature of symptom onset. Complex multi-faceted interventions to promote rapid help seeking and to facilitate prompt onward referral from primary care should be developed.

INTRODUCTION

Rheumatoid arthritis (RA) is a chronic inflammatory disease affecting approximately 1% of the population. RA is associated with significant morbidity in large part as a consequence of extra-articular comorbidities associated with systemic inflammation. In the UK, it has been estimated that RA costs the National Health Service (NHS) around £560 million per year and that additional costs to the economy of sick leave and work-related disability total £1.8 billion per year. The first 3 months following the onset of RA symptoms represents an important therapeutic window. Treatment during this phase improves long-term clinical outcomes, increasing the proportion of patients whose disease enters remission, reducing RA related joint damage and reducing the eventual need for joint replacement surgery. Therefore, it is vital that patients are seen by rheumatologists rapidly following the onset of RA symptoms to allow the rapid introduction of disease-modifying anti-rheumatic drug (DMARD) treatment. However, despite increased recognition of the benefits of early treatment there remains considerable delay between symptom onset and the initiation of therapy. Indeed a report by the UK's
National Audit Office (NAO) in 2009 estimated that only 10% of patients with RA were treated within 3 months of symptom onset. The NAO’s modelling suggested significant financial benefits for the broader economy and quality of life benefits for the individual if the proportion of patients treated earlier was increased.3

The patient’s pathway to care can be delayed for a number of reasons, including delays on the part of the patient in recognising the significance of the early symptoms of RA.14–16 Recent research has linked patients’ perceptions of RA and coping styles to the length of time taken to seek help.17 Before seeking medical help from a physician, patients may seek help from a range of services including complementary therapists, pharmacists and telephone and online services. However, the use of these services at the onset of inflammatory arthritis has not been fully explored. Primary healthcare professionals often find the early symptoms of RA difficult to distinguish from those of other rheumatic diseases, making timely and appropriate referrals to rheumatologists challenging.18 19 There may thus be delays in healthcare professionals making a referral to a rheumatologist and also in assessment at the secondary care level, contributing further to the delay in making a diagnosis and commencing appropriate therapy.

Several studies conducted across a range of countries have shown long delays between the onset of symptoms and a patient’s first consultation with a rheumatologist.20–25 However, data related to lengths of time between the onset of inflammatory musculoskeletal symptoms and first seeing a GP, between first seeing a GP and being referred to a rheumatologist and being seen by a rheumatologist following referral were not available across multiple NHS Trusts in multiple regions of the UK at the time of this study.

AIM

The aim of this study was to investigate the extents of delay in assessment of patients with RA and unclassified arthritis. Specifically the study assessed extents of delay at the level of the patient in seeking help from the general practitioner, the general practitioner in referring to a rheumatologist and the rheumatologist in assessing the patient following referral. The relationships between extents of delay and clinical and demographic variables were explored and data captured relating to sources of information, help and advice used by patients prior to GP consultation.

METHODS

A questionnaire based survey of consecutively presenting patients with a new onset of RA or unclassified inflammatory arthritis was undertaken in England and Scotland. Networks such as the Early Rheumatoid Arthritis Network24 and the National Institute for Health Research Clinical Research Network25 were used to identify rheumatology centres to participate in this study. RJS also promoted the study during abstract presentations at British Society for Rheumatology meetings.

Data were collected from rheumatology departments in 34 NHS Trusts. Rheumatology departments were secondary care based, although one rheumatology department (Sandwell and West Birmingham Hospitals) operated clinics in both hospital and community settings. Eligible patients were recruited on their first or second visit to the rheumatology department following a primary care referral (data were not collected on the numbers of patients whose data were collected at their first visit or at their second visit). Rheumatologists were asked to approach consecutively presenting patients who met the eligibility criteria. Eligible patients were newly referred adults (aged ≥18 years) with clinically apparent synovial swelling of one or more joints who had either a new onset of RA (according to 2010 American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) criteria26 or unclassified arthritis (UA; defined as a failure to fulfil classification criteria for another inflammatory rheumatic disease). Patients with UA were recruited, as in many cases patients with UA at initial secondary care assessment progression to RA over time.27

Data were collected using two questionnaires (available from the corresponding author on request). First, following consent, the recruiting healthcare professional, with the patient present, completed a questionnaire that captured data on extents of delays between (1) symptom onset and seeing a healthcare professional (from herein referred to as ‘patient delay’, these data were gathered from the patient’s account by the recruiting healthcare professional); (2) seeing a general practitioner and being referred to a rheumatologist (from herein referred to as ‘general practitioner delay’, these data were gathered from the patient’s account by the recruiting healthcare professional); and (3) being referred to a rheumatologist and seeing a rheumatologist (from herein referred to as ‘hospital delay’, these data were gathered from referral letters and hospital notes). Data were also gathered on (1) demographic variables including the patient’s age, gender, education, employment status and postcode; deprivation ranks were calculated from postcode data using Geocovert 2010 which produced an Index of Multiple Deprivation (IMD) score,28 (2) clinical variables including the mode of symptom onset (palindromic (defined as intermittent symptoms) vs non-palindromic (defined as persistent symptoms)), rapidity of symptom onset (acute vs insidious; an acute onset was typically viewed as an onset of symptoms which came on rapidly over 24–48 hours), duration of morning stiffness, swollen and tender joint counts, Disease Activity Score 28 and fulfilment of 2010 ACR/EULAR criteria for classification of RA.26

In addition, via a separate questionnaire that patients completed by themselves, patients provided data on actions taken in relation to their symptoms prior to seeking help from primary care. The variables captured
were informed by previous qualitative research, including patient interviews and interviews with healthcare professionals. In addition, we had input from Patient Research Partners and the questions asked were validated and assessed for reliability.20

**Patient and public involvement**

Patient and public involvement was an important element of this study. Patient representatives from Sandwell and West Birmingham Hospitals NHS Trust were involved in the study design, advised on the content of patient facing materials including participant information sheets and consent forms and the content of questionnaires including questions related to actions taken by patients prior to consulting their GPs. Patients were members of the Project Management Group reviewing study recruitment and supporting the group in developing approaches to ensure that recruitment proceeded to time and target.

**Analysis**

To ensure that the data met parametric assumptions, the distribution and levels of multicollinearity between variables were checked. Data on patient delays, general practitioner delays and hospital delays were not normally distributed; therefore, log values of these delay data were created to generate normally distributed variables.

For each of the outcomes patient delay, general practitioner delay and hospital delay a general linear model was used with main effects and two-way interactions for the following explanatory variables: gender, ethnicity, IMD score, age, education, employment status, mode of onset, rapidity of onset, patient reported family history of RA and RA versus UA. For each outcome any two-way interactions which were not significant were removed in a backwards stepwise fashion, with the pairings with the highest p values being removed first. All main effects were retained, so that the final model for each outcome included all ten explanatory variables and any significant two-way interactions (p<0.01). All significant main effects and interactions are reported in the Results section.

**RESULTS**

**Participant characteristics**

Data were collected from 856 patients between 2011 and 2014. Patients were withdrawn from the study due to incomplete data (21 cases) and ineligibility (13 cases in whom there was no clinical synovitis reported at recruitment). Data were thus analysed from 822 patients of whom 68.5% were female with a mean age of 55 years. Characteristics of patients are presented in table 1.

**Intervals between symptom onset and first rheumatology consultation**

Overall, the median time between symptom onset and seeing a rheumatologist was 27.2 weeks (IQR 14.1–66 weeks); only 20% of patients were seen within the first 3 months following symptom onset. The median patient delay was 5.4 weeks (IQR 1.4–26.3 weeks). The median general practitioner delay was 6.9 weeks (IQR 2.3–20.3 weeks) with patients making a mean of 4 GP visits before being referred. The median hospital delay was 4.7 weeks (IQR 2.9–7.5 weeks).

Palindromic onset is defined as intermittent symptoms, while non-palindromic onset is defined as persistent symptoms. Acute onset is defined as symptoms which came on rapidly over 24–48 hours, while insidious onset is defined as symptoms which developed slowly over an extended period of time. Patients with a palindromic symptom onset had a significantly longer patient delay than those with a non-palindromic onset (9.3 weeks (IQR 2–43 weeks) vs 4.3 weeks (IQR 1–17 weeks); p<0.001, t-test). Furthermore, those with an acute symptom onset had significantly shorter patient delays than those with an insidious symptoms onset (2.4 weeks (IQR 1–6.6 weeks) vs 11.1 weeks (IQR 4–44 weeks); p<0.001, t-test).

**Resources used before seeking help from primary care**

Patients reported taking a range of actions in relation to their symptoms before seeking help from their GP and in some cases these actions were associated with longer delays in GP consultation (see table 2). Most often, patients reported purchasing tablets from ‘the chemist’, although only a small proportion actually reported

### Table 1: Demographic and disease-related characteristics of patients

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Percentage (Number)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gender</td>
<td>68.5% (563)</td>
</tr>
<tr>
<td>Age, years</td>
<td>57 (45–67)</td>
</tr>
<tr>
<td>Diagnosis of RA</td>
<td>73% (603)</td>
</tr>
<tr>
<td>Ethnicity</td>
<td></td>
</tr>
<tr>
<td>Black British</td>
<td>6.0% (49)</td>
</tr>
<tr>
<td>South Asian</td>
<td>7.7% (63)</td>
</tr>
<tr>
<td>White British</td>
<td>84.9% (698)</td>
</tr>
<tr>
<td>Other</td>
<td>1.5% (12)</td>
</tr>
<tr>
<td>Self-reported family history of RA</td>
<td>34.9% (287)</td>
</tr>
<tr>
<td>Palindromic onset</td>
<td>42.8% (352)</td>
</tr>
<tr>
<td>Acute onset</td>
<td>35.9% (295)</td>
</tr>
<tr>
<td>Duration of morning stiffness, minutes</td>
<td>60 (10–120)</td>
</tr>
<tr>
<td>DAS28</td>
<td>4.88 (3.98–5.80)</td>
</tr>
<tr>
<td>Health Assessment Questionnaire (HAQ)</td>
<td>1.13 (0.50–1.73)</td>
</tr>
<tr>
<td>Tender joint count</td>
<td>9 (4–18)</td>
</tr>
<tr>
<td>Swollen joint count</td>
<td>5 (2–10)</td>
</tr>
</tbody>
</table>

Data are presented as either percentage (number) or median (IQR) as appropriate.

Palindromic onset is defined as intermittent symptoms, while non-palindromic onset is defined as persistent symptoms. Acute onset is defined as symptoms which came on rapidly over 24–48 hours, while insidious onset is defined as symptoms which developed slowly over an extended period of time. Patients with a palindromic symptom onset had a significantly longer patient delay than those with a non-palindromic onset (9.3 weeks (IQR 2–43 weeks) vs 4.3 weeks (IQR 1–17 weeks); p<0.001, t-test). Furthermore, those with an acute symptom onset had significantly shorter patient delays than those with an insidious symptoms onset (2.4 weeks (IQR 1–6.6 weeks) vs 11.1 weeks (IQR 4–44 weeks); p<0.001, t-test).

**Acute onset**

35.9% of patients had an acute symptom onset (355 patients). They had a significantly longer delay than those with a non-palindromic onset (9.3 weeks (IQR 2–43 weeks) vs 4.3 weeks (IQR 1–17 weeks); p<0.001, t-test).

**Insidious onset**

59.6% of patients had an insidious symptom onset (505 patients). They had a significantly shorter delay than those with palindromic onset (9.3 weeks (IQR 2–43 weeks) vs 11.1 weeks (IQR 4–44 weeks); p<0.001, t-test).

**Resources used before seeking help from primary care**

Patients reported taking a range of actions in relation to their symptoms before seeking help from their GP and in some cases these actions were associated with longer delays in GP consultation (see table 2). Most often, patients reported purchasing tablets from ‘the chemist’, although only a small proportion actually reported...
This research highlights that delays in primary care are long, and a major contributor to overall delays speaking to a pharmacist. Other actions reported by patients included applying heat or cold packs to joints or buying joint supports.

Thirty-seven per cent of patients reported looking on the internet (eg, visiting the NHS direct website, Arthritis Research UK website and searching for information using search engines such as Google). Patients also reported seeking support via a telephone helpline; 5.7% described calling the NHS direct helpline or another telephone health advice service. 3.7% sought help in the workplace (eg, from an occupational nurse), 2% of patients went directly to the accident and emergency department and 1% attended an NHS walk-in centre.

**Multivariate analysis: patient delay**

The interaction model showed main effects for mode of onset (palindromic vs non-palindromic; F=26.65, p<0.01) and rapidity of onset (acute vs insidious; F=65.36, p<0.01). An interaction was found between palindromic onset and gender (F=45.658, p<0.01); men with a palindromic onset waited significantly longer before seeking help.

**Multivariate analysis: general practitioner delay**

A main effect was found for ethnicity (F=6.26, p<0.01). Significant differences in general practitioner delay were found between white British and South Asian patients (6.2 weeks (IQR 2–18.6) vs 22 weeks (IQR 6.5–39.8); p<0.001) and between white British and black British patients (6.2 weeks (IQR 2–18.6) vs 11.1 weeks (IQR 4.3–21.7); p<0.001). No significant difference was found between South Asian and black British patients (p=1.000).

A main effect was also found for family history (F=5.89, p<0.01); the median general practitioner delay for those with a self-reported family history of RA was 9 weeks (IQR 2.4–25.7), while general practitioner delay for those with no family history was 6.3 weeks (IQR 2.3–19). Interactions at a statistically significant level (<0.01) were not found.

**Multivariate analysis: hospital delay**

The original model included main effects and two-way interactions for the following explanatory variables: gender, ethnicity, IMD score, age, education, employment status, mode of onset, rapidity of onset, family onset and RA versus UA. None of the main effects or interactions (when removed backwards) were significant in predicting the delay between referral and being seen in secondary care.

**DISCUSSION**

International guidelines recommend that the treatment of RA should begin as soon as possible after the onset of symptoms, ideally aiming to capture patients within the first 3 months following symptom onset. However, this large UK study of delays in access to care for patients with RA found that the median patient delay in seeking help at the onset of symptoms was 5.4 weeks, while the median delay between seeing a healthcare professional and being referred was 6.9 weeks. Our study highlights that only 20% of patients were seen within the first 3 months of symptom onset. This appears to be lower than the rate reported in other European countries, for example, a recent study in Austria reported that 38% of patients were seen within the first 3 months. The present study also found an average delay of 4.7 weeks from referral until the patient was seen by a rheumatologist, similar to figures reported in the NAO report. Unlike our previous study conducted at a single centre in the UK where patient delay accounted for the largest element of delay, we found that GP delay was the largest contributor to overall delay; patient delay was less than we had previously reported in our single centre study.

This research highlights that delays in primary care are long, and a major contributor to overall delays

---

**Table 2** Actions taken by patients with inflammatory arthritis before seeking help from their GP with comparison made for patient delay between those who did and did not undertake this action using independent t-tests

<table>
<thead>
<tr>
<th>Actions taken before seeking help from GP</th>
<th>% (number) of participants undertaking this action</th>
<th>Median (IQR) patient delay in weeks for those undertaking this action</th>
<th>Median (IQR) patient delay in weeks for those not undertaking this action</th>
<th>P value*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bought tablets from the chemist</td>
<td>51.1% (273 out of 534)</td>
<td>6.9 (2–30.7)</td>
<td>4.7 (1.4–23)</td>
<td>0.036</td>
</tr>
<tr>
<td>Used an ice or heat pack on joint</td>
<td>47.8% (254 out of 531)</td>
<td>7.6 (2–30.3)</td>
<td>4.9 (2–26.1)</td>
<td>0.045</td>
</tr>
<tr>
<td>Took baths</td>
<td>47.4% (251 out of 529)</td>
<td>6.3 (2–30.4)</td>
<td>5.6 (2–26.1)</td>
<td>0.473</td>
</tr>
<tr>
<td>Bought joint supports (splints, tubi-grips, etc)</td>
<td>37.4% (198 out of 529)</td>
<td>4.4 (2.1–18.6)</td>
<td>5.1 (2–26.9)</td>
<td>0.362</td>
</tr>
<tr>
<td>Used alternative therapies</td>
<td>25.2% (134 out of 531)</td>
<td>8.3 (2–42.1)</td>
<td>5.3 (2–26.3)</td>
<td>0.020</td>
</tr>
<tr>
<td>Bought products from a health shop</td>
<td>19.0% (101 out of 532)</td>
<td>5.9 (2–36.3)</td>
<td>5.9 (2–26)</td>
<td>0.182</td>
</tr>
<tr>
<td>Modified diet</td>
<td>14.4% (76 out of 529)</td>
<td>6 (2.1–35.3)</td>
<td>6.1 (2–26.3)</td>
<td>0.183</td>
</tr>
<tr>
<td>Used prayer or sought spiritual guidance</td>
<td>8.4% (45 out of 534)</td>
<td>4.4 (2.1–18.6)</td>
<td>6.3 (2–26.9)</td>
<td>0.941</td>
</tr>
<tr>
<td>Spoke to a pharmacist</td>
<td>7.9% (41 out of 521)</td>
<td>5.9 (2–38.1)</td>
<td>5.9 (2–26.3)</td>
<td>0.544</td>
</tr>
</tbody>
</table>

*P value for comparison of those who did and did not undertake this action.
between symptom onset and the first rheumatology visit. General practitioners are faced with a number of barriers to identifying patients with newly presenting RA including the often non-specific nature of symptoms at the earliest stages of RA. Research is under way to define symptom complexes most predictive of RA development in patients with newly presenting musculoskeletal symptoms. For example, a questionnaire has been developed and validated to capture such symptoms in patients presenting with joint symptoms which by history are suggestive of an underlying inflammatory cause and data are currently being collected from such patients in secondary care based longitudinal observational cohort studies to identify symptoms that may predict RA development. Furthermore an assessment of primary care databases has identified a range of symptoms including hand related joint symptoms, morning stiffness and carpal tunnel syndrome type symptoms as being ones with which patients frequently present to the GP prior to the point at which the GP refers the patient to a rheumatologist or records a diagnosis of RA. It is likely that a combination of education, and evidence based referral algorithms, will be needed to ensure that suspected cases are referred early. For example, in Fife, Scotland, GPs did not have access to rheumatoid factor testing during the course of our study, and used guidelines with pictorial representations to help identify early synovitis (H Harris, personal communication, 2015). Fife was a participating centre in this study, and was found to have the shortest GP referral time of all centres surveyed. Furthermore, facilitating access to secondary care, for example, through the establishment of rapid assessment clinics whose main aim is to identify whether the patient does or does not have synovitis has been shown to significantly reduce delays in the assessment of patients. A limitation of our research is that the study was not able to assess regional differences across NHS Trusts. A study comparing delays and referral patterns between hospitals with local policies and practices which may influence the time between onset and first consultation would be useful and an international study would be particularly helpful. In addition, this study did not examine the distances between patients’ homes and their local GP surgeries, and hospitals and so we were unable to assess whether physical distance between the patient’s home and the GP surgery or hospital influenced delay.

A number of factors were found to influence GP delay including ethnicity. Some studies in the field of oncology have also found that people from ethnic minority backgrounds face longer GP delays. In the context of RA, it is possible that the early symptomatology of patients from ethnic minority backgrounds is different from, and less typical of RA than that of, patients of white British background, thus making recognition more challenging for GPs. Data certainly exist that the clinical phenotype of established RA differs in patients of South Asian origin compared with patients of white British origin, though data relating the clinical presentations of RA in these groups are lacking. Furthermore, it is unclear why a self-reported family history of RA would be associated with longer delays although it is important to recognise that GPs may not have elicited this information from the patient. Qualitative approaches may be helpful to address some of these issues in the future.

Previous qualitative studies and a meta-synthesis have identified barriers to help seeking at the onset of RA. The present study identifies that before seeking formal medical attention, people experiencing the early symptoms of RA seek information and help from a number of alternative sources and often self-medicate. We identified that buying tablets from a pharmacy and using heat or ice on joints were significantly associated with longer patient delays. This finding highlights that some self-management behaviours, particularly those linked to accessing pharmacy services can negatively impact on the time it takes to seek help; this needs further exploration. Factors previously suggested to be associated with delays in GP consultation included an insidious onset of mild symptoms and a lack of knowledge about RA, personal susceptibility to RA and the availability of treatments to slow disease progression. In our national sample 64.1% of people describe an insidious onset of RA, and 42.8% describe a palindromic onset of RA. Therefore, a large proportion of patients surveyed experienced a slow and/or intermittent onset of their inflammatory joint symptoms. Our quantitative data are consistent with results from qualitative studies, demonstrating that the mode and rapidity of onset of symptoms is significantly associated with patient delays.

This study has a number of limitations. First, the interval between first consultation with a rheumatologist and initiation of DMARD treatment was not measured. Any additional delay in commencing DMARD treatment will negatively impact the patient and variables associated with delays at this level should be assessed in future studies. Second, during the course of this study, a number of guidelines related to RA management were published which may have influenced practice, and patterns of referral. We were not able to explore the relationships between the availability/local adoption of guidelines and delays in the assessment of patients. Future investigation should assess the impact of policy changes on patterns of help-seeking, referral and assessment. Third, the rheumatology centres participating in this study were self-selecting, therefore, there may be biases in the characteristics of the rheumatology centres which participated in this study. For example, the participating rheumatology units may have had a particular interest in early arthritis. Only a study which recruited consecutive patients from all rheumatology units across the UK would be able to provide a truly national picture. Fourth, while we were able to document the length of delay at a primary care level there were important variables which may have influenced this delay which we did not record and so were unable to explore. For example, it would have been helpful to have access to results of tests performed in primary care to assess...
whether levels of inflammatory markers or RA related autoantibodies measured in primary care influenced the rapidity of referral from primary care. Indeed a recent quantitative survey of GPs’ anticipated actions in primary care when dealing with patients with suspected RA suggest that results of these tests may influence GP behaviours.44 Future research should address this. Similarly, a number of secondary care related variables may have influenced the extent of secondary care delay including the number of rheumatologists at each Trust, whether a dedicated early arthritis clinic was in place and approaches taken to the triage of referrals. Data relating to these variables were not collected though future work addressing issues of delay should address these important issues. Fifth, data relating to the dates of onset of symptoms and initial GP consultation were gathered from patients’ histories, and therefore relied on patient recollection with a possible associated error. However, a previous study addressing delays in the assessment of patients with RA, compared patient accounts of their journeys to first rheumatology consultation against medical records and highlighted the accuracy of patient recollection in relation to dates found to be documented in primary care records.20 This, to some extent, validates our approach of using patient memory to define the dates of symptom onset and initial GP presentation. An alternative approach would be a longitudinal observational study in the general population to track the development of symptoms and the relationship between that and GP consultation, GP referral and secondary care assessment. A challenge with this approach is the low incidence of RA and thus the requirement for a very large sample size. One could potentially enrich the population for RA risk by, for example, following individuals who are at increased risk of RA (eg, the first degree relatives of patients with RA). However, one of the challenges with this strategy is that simply being involved in such a study may influence subsequent patient and GP behaviour.

While delays in primary care are the largest contributor to overall delay, patient delay and hospital delay represent important components. This study found that the nature of symptom onset influenced how quickly patients with RA sought help, suggesting that those with an acute onset of persistent symptoms seek help faster than those with insidious and palindromic onsets. Interventions to encourage rapid help seeking should consider highlighting the frequently insidious onset of RA to members of the public stressing that help should be sought even when symptoms are mild. However, even those with a rapid onset of persistent symptoms often delayed for prolonged periods before seeking help. We have previously shown that members of the public view musculoskeletal symptoms, even those with clear inflammatory features, as less worrisome and less requiring rapid assessment as compared with symptoms of other common diseases such as ischaemic type chest pain or bowel disturbance with associated rectal blood loss.45 Enhanced public education to highlight the significance of inflammatory type musculoskeletal symptoms is thus likely to be needed. Interventions at multiple levels, including at the levels of the public, the services which members of the public consult after the onset of symptoms (eg, pharmacies), primary care and secondary care will be needed to reduce overall delays in access to appropriate specialists.

Author affiliations
1Division of Psychology, Nottingham Trent University, Nottingham, UK
2Wellcome Trust Clinical Research Facility, Queen Elizabeth Hospital Birmingham, Birmingham, UK
3Arthritis Research UK Primary Care Centre, Keele University, Keele, UK
4Institute of Applied Health Research, University of Birmingham, Birmingham, UK
5Independent Research Consultant, Brussels, Belgium
6UCL School of Pharmacy, UCL, London, UK
7Department of Rheumatology, Derby Teaching Hospitals NHS Foundation Trust, Derby, UK
8Department of Rheumatology, St Georges University Hospital NHS Foundation Trust, London, UK
9Institute of Inflammation and Ageing, University of Birmingham, Birmingham, UK
10Department of Rheumatology, Sandwell and West Birmingham Hospitals NHS Trust, Birmingham, UK

Acknowledgements We would like to thank the staff at the Rheumatology Departments who collected data for this study. We would also like to thank patient research partners at Sandwell and West Birmingham Hospitals NHS Trust for their help and support with this study.


Contributors RJS, CJ, SH-M, CM, KS, RH, CD, PK and KR made substantial contributions to the conception or design of the work. The acquisition of data was undertaken by RJS, KR, PK and CD. RJS, CJ and SH-M facilitated patient and public involvement in the design, delivery and interpretation of this study. The analysis and interpretation of data were undertaken by RJS, PN and KR. RJS, PN CJ, SH-M, CM, KS, RH, CD, PK and KR were involved in drafting the work and revising it critically for important intellectual content. RJS, CJ, SH-M, CM, KS, RH, CD, PK and KR gave final approval of the version published. All authors agree to be accountable for all
aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

**Funding** This article presents independent research funded in part by the National Institute for Health Research (NIHR) under the Research for Patient Benefit Programme (funder’s reference PB-PG-1208-1114). CM is funded by the National Institute for Health Research (NIHR) Collaborations for Leadership in Applied Health Research and Care West Midlands, the NIHR School for Primary Care Research and a NIHR Research Professorship in General Practice (NIHR-RP-2014-04-026). CJ is part-funded by the NIHR Collaborations for Leadership in Applied Health Research and Care West Midlands. RH is part-funded by North Thames CLARHC and his contribution was also supported by an NIHR Senior Investigator Award. KS is funded and Care West Midlands. RH is part-funded by the NIHR Collaborations for Leadership in Applied Health Research and Care West Midlands. KR is supported by the National Institute for Health Research (NIHR) Birmingham Biomedical Research Centre.

**Disclaimer** The views expressed in this publication are those of the authors and not necessarily those of the NHS, the National Institute for Health Research or the Department of Health and Social Care.

**Competing interests** None declared.

**Patient consent for publication** Not required.

**Ethics approval** Ethical approval was obtained from South Birmingham Research Ethics Committee (reference no. 10/H1207/98). Data were stored in a secure location and protected by multiple security systems.

**Provenance and peer review** Not commissioned; externally peer reviewed.

**Data sharing statement** Unpublished data are available from the corresponding author by request.

**Open access** This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

**REFERENCES**


